title: Elevation of oxidized DJ-1 in the brain and erythrocytes of Parkinson disease model animals.
abstract: DJ-1, the causative gene of a familial form of Parkinson's disease (PD), has been reported undergo oxidation preferentially at the 106th cysteine residue (Cys-106) under oxidative stress. Recently, it has been found that the levels of oxidized DJ-1 in erythrocytes of unmedicated PD patients are markedly higher than those in medicated PD patients and healthy subjects. In the present study, we examined the changes in oxidized DJ-1 levels in the brain and erythrocytes of PD animal models using specific antibodies against Cys-106-oxidized DJ-1. Treatment with PD model compounds such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 6-hydroxydopamine significantly elevated the levels of oxidized DJ-1 in erythrocytes. Immunohistochemical analysis also revealed that the number of oxidized DJ-1 antibody-positive cells in the substantia nigra of MPTP-treated mouse increased in a dose-dependent manner. These results suggest that the oxidative modification of DJ-1 in the brain and erythrocytes is involved in the pathogenesis of PD in animal models.
authors: Health Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Ikeda, Osaka, Japan.
authors: Yoko Ogawa
authors: YO
authors: Akazawa
authors: Yoshiro
authors: Y
authors: Saito
authors: Takao
authors: T
authors: Hamakubo
authors: Yoshinori
authors: Y
authors: Masuo
authors: Yasukazu
authors: Y
authors: Yoshida
authors: Keiko
authors: K
authors: Nishio
authors: Mototada
authors: M
authors: Shichiri
authors: Tomohiro
authors: T
authors: Miyasaka
authors: Hiroko
authors: H
authors: Iwanari
authors: Yasuhiro
authors: Y
authors: Mochizuki
authors: Tatsuhiko
authors: T
authors: Kodama
authors: Noriko
authors: N
authors: Noguchi
authors: Etsuo
authors: E
authors: Niki
mesh_terms: D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000494:pharmacology; D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D002395:Catecholamines / Q000378:metabolism; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D004195:Disease Models, Animal; D004334:Drug Administration Schedule; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D004912:Erythrocytes / Q000187:drug effects / Q000378:metabolism*; D051379:Mice; D015513:Oncogene Proteins / Q000378:metabolism*; D016627:Oxidopamine / Q000633:toxicity; D010300:Parkinson Disease / Q000209:etiology / Q000473:pathology*; D054464:Peroxiredoxins; D000071617:Protein Deglycase DJ-1; D051381:Rats; D013997:Time Factors
chemical_list: D002395:Catecholamines; D015513:Oncogene Proteins; D016627:Oxidopamine; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D054464:Peroxiredoxins; C503466:PARK7 protein, mouse; D000071617:Protein Deglycase DJ-1